Scleroderma can be fatal, though it varies enormously depending on which organs are affected and how quickly the disease progresses. Population-based studies put the overall death rate at roughly one-and-a-half to two times that of the general population, with one large cohort reporting survival rates of about 87% at five years and 61% at fifteen years after diagnosis.1PubMed Central. Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality What has changed dramatically over the past few decades is which complications are most likely to kill, and which treatments have pulled certain once-devastating outcomes back from the brink.
How the Leading Cause of Death Has Shifted
In the 1970s, the kidney crisis that can accompany scleroderma was by far the biggest killer. At that time, about 42% of scleroderma-related deaths were caused by renal crisis. By the early 2000s, that figure had dropped to around 6%, largely because a class of blood-pressure drugs called ACE inhibitors turned what had been an almost universally lethal complication into a survivable one.2PubMed Central. Changes in causes of death in systemic sclerosis, 1972-2002 That was a genuine medical success story, but the void left behind was filled by lung disease. Over the same thirty-year window, deaths from pulmonary fibrosis rose from 6% to 33% of scleroderma-related deaths, and deaths from pulmonary hypertension also climbed significantly. Today the lungs, through both fibrosis and high blood pressure in the pulmonary arteries, are the leading cause of death in scleroderma.2PubMed Central. Changes in causes of death in systemic sclerosis, 1972-2002
This shift matters practically. If you or someone you know has scleroderma, the surveillance priorities in 2025 are different from what they were a generation ago. Lung function testing and regular echocardiograms to screen for rising pressures in the pulmonary arteries are now central to keeping people alive longer.
Pulmonary Fibrosis and Pulmonary Hypertension
Pulmonary fibrosis, the scarring of lung tissue, occurs in most people with scleroderma to some degree. In roughly 15% of patients, it progresses to severe restrictive lung disease.3PubMed. Interstitial lung disease in scleroderma That 15% figure might sound reassuring at first glance, but interstitial lung disease remains the single leading driver of both illness and death in systemic sclerosis.4PubMed. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review The challenge is that predicting who will progress from mild scarring to life-threatening restriction remains difficult. Certain risk factors help: having the diffuse skin subtype, testing positive for anti-topoisomerase I antibodies (also called anti-Scl-70), and showing low lung function numbers at the time of diagnosis all point toward a worse trajectory.3PubMed. Interstitial lung disease in scleroderma
Pulmonary arterial hypertension, or PAH, is a separate but sometimes overlapping problem. In PAH, the small arteries in the lungs narrow and stiffen, forcing the right side of the heart to work harder until it eventually fails. PAH can develop in up to about a quarter of scleroderma patients and is one of the leading causes of death in this population.5PubMed Central. Pulmonary arterial hypertension associated with systemic sclerosis It can occur on its own or on top of existing lung fibrosis, and the combination is particularly dangerous.6PubMed. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease Detecting PAH early, before symptoms like breathlessness at rest appear, is one of the most impactful things clinicians can do. A disproportionate drop in the lung’s ability to transfer carbon monoxide, measured by a test called DLCO, can flag patients who need further investigation even before they feel short of breath.7Internal Medicine Journal / Wiley Online Library. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment
Heart, Kidney, and Gut Involvement
The lungs get the most attention, but other organs can also fail in ways that prove fatal. Cardiac disease in scleroderma, which can include scarring of the heart muscle, conduction problems, and heart failure, affects roughly 15 to 35% of patients and accounts for about 27% of scleroderma-related deaths.8PubMed Central. Cardiac disease in systemic sclerosis: a narrative review Heart involvement is insidious because it often doesn’t announce itself with obvious symptoms until it is advanced.
Scleroderma renal crisis, the kidney emergency that dominated mortality statistics decades ago, still occurs and can still kill, but ACE inhibitors have changed the math considerably. Before these drugs were available, one-year survival after renal crisis was only about 15%. With ACE inhibitor treatment, that jumped to 76%.9PubMed. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors Even patients who end up on dialysis have a chance of recovering kidney function if they stay on ACE inhibitors. In one study, over half of patients who continued taking ACE inhibitors while on dialysis were eventually able to stop dialysis altogether, compared with none of the patients who stopped the medication.9PubMed. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors Despite this progress, renal crisis still carries serious risk, especially in older patients, men, and those whose blood pressure is not controlled quickly enough.10PubMed. Long-term outcomes of scleroderma renal crisis
The gastrointestinal tract is another underappreciated threat. The majority of scleroderma patients have some GI symptoms, from acid reflux to difficulty swallowing, and these are often treated as nuisances rather than red flags. But severe GI disease, including malabsorption, pseudo-obstruction, and the need for intravenous feeding, develops in a meaningful fraction of patients.11PubMed Central. Gastrointestinal involvement in systemic sclerosis: Effects on morbidity and mortality and new therapeutic approaches In one cohort study, the probability of developing severe GI disease within four years of diagnosis was estimated at 16%, and patients with that complication had more than double the risk of dying compared with those without it after adjusting for age and sex.12Rheumatology. Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality
Who Faces the Greatest Risk
Not everyone with scleroderma faces the same prognosis. The single biggest divide is between the diffuse cutaneous subtype, where skin thickening spreads rapidly over large areas of the body and internal organs are more frequently affected, and the limited cutaneous subtype, where skin changes are largely confined to the hands, face, and forearms. In a large international registry, fifteen-year survival was about 55% for the diffuse group compared with roughly 69% for limited and over 92% for the uncommon “sine scleroderma” form, where internal organ damage occurs without significant skin thickening.13PubMed Central. Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database
Beyond subtype, several other factors consistently predict worse outcomes. Older age at onset, male sex, and diffuse skin involvement all track with higher mortality. So do certain autoantibody profiles. Anti-topoisomerase I antibodies are linked to lung fibrosis, while anti-RNA polymerase III antibodies are associated with kidney crisis, and anti-centromere antibodies, paradoxically, tend to predict somewhat better overall survival.14PubMed Central. Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature From the Pittsburgh Scleroderma Databank, ten-year survival in diffuse disease ranged from 61% for those with anti-U3-RNP antibodies to 75% for those with anti-RNA polymerase III, while in limited disease it ranged from 65% with anti-Th/To to 88% with anti-U1-RNP.15PubMed. Prognostic markers for systemic sclerosis These numbers illustrate how much the antibody profile shapes what to expect.
Race is another powerful factor, and one that is still not well enough recognized. In a twenty-year study at Johns Hopkins, African American patients had a ten-year mortality of 43% compared with 35% for white patients, and after adjusting for age and disease duration, Black patients had an 80% higher risk of dying.16PubMed Central. Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature A nationwide US study reinforced this, finding that the median age of scleroderma death was 57 in Black individuals versus 70 in white individuals, with Black patients facing five times the odds of dying before age 65 compared to white patients.17PubMed Central. Worsening premature death burden gap from systemic sclerosis in men and black persons: A US nationwide population-based study That thirteen-year gap in median age at death is stark. Men also die younger on average, with a median age of 63 compared to 68 for women.17PubMed Central. Worsening premature death burden gap from systemic sclerosis in men and black persons: A US nationwide population-based study
Cancer Risk in Scleroderma
People with scleroderma have a higher risk of developing cancer than the general population. The reasons are not entirely settled. Chronic inflammation and tissue damage may create a hospitable environment for malignancy, immunosuppressive therapies used to manage the disease could play a role, or both processes might share a common trigger.18PubMed Central. Cancer and Scleroderma Lung cancer is one of the more closely watched associations, given how much lung tissue is already under stress from fibrosis. Breast cancer and certain hematologic cancers have also been flagged in registry studies. Cancer surveillance in scleroderma patients therefore deserves the same routine attention as lung function tests and echocardiograms, even though it often receives less.
Overlap Syndromes and Compounded Risk
Some patients develop scleroderma alongside another autoimmune disease, a situation called an overlap syndrome. When scleroderma overlaps with polymyositis (an inflammatory muscle disease), the prognosis worsens meaningfully. In one study, five-year survival was 82% in the overlap group versus 93% in those with scleroderma alone, and ten-year survival dropped to 68% versus 87%, with the adjusted risk of death more than doubled.19PubMed. Patients with Systemic Sclerosis/polymyositis Overlap Have a Worse Survival Rate Than Patients Without It The leading cause of death in both groups was cardiopulmonary disease.
Interestingly, not all overlap syndromes carry the same penalty. A large study using the European Scleroderma Trials and Research Group (EUSTAR) database found that overlap scleroderma and non-overlap scleroderma were broadly similar in terms of mortality when looking across all overlap types. But the presence of concomitant Sjögren syndrome alongside scleroderma stood out as a particularly strong predictor of death in that analysis.20PubMed. Systemic sclerosis overlap and non-overlap syndromes share clinical characteristics but differ in prognosis and treatments If you have scleroderma combined with dry eyes, dry mouth, and other Sjögren symptoms, it is worth flagging to your rheumatologist explicitly, since the combination carries distinct prognostic weight.
Treatments That Have Changed Survival
There is no cure for scleroderma, but several treatments have meaningfully changed the survival landscape. The ACE inhibitor story for renal crisis, covered earlier, is the clearest example of a single drug class pulling a complication back from near-certain death.
For severe diffuse scleroderma that is progressing rapidly, autologous stem cell transplantation has emerged as an aggressive but effective option. In a randomized trial, event-free survival at 54 months was 79% in patients who received a transplant compared with 50% in those treated with conventional immunosuppression using cyclophosphamide. At 72 months, overall survival was 86% versus 51%.21PubMed Central. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma A longer-term follow-up study showed that after a median of about five years, over 80% of transplanted patients had a beneficial clinical response, with skin thickening improving and organ function stabilizing.22Annals of the Rheumatic Diseases. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis The catch is that the transplant itself carries upfront danger. Treatment-related deaths are higher with stem cell transplantation than with conventional immunosuppressive therapy, though the survival curves cross within the first couple of years and then increasingly favor transplantation.23Modern Rheumatology. Benefits and risks of haematopoietic stem cell transplantation for systemic sclerosis: A systematic review and meta-analysis This means patient selection is critical: the procedure makes the most sense for people whose disease is severe enough that the long-term risk of doing nothing outweighs the short-term risk of the transplant.
When Treatment Itself Becomes Dangerous
The medications used to manage scleroderma’s internal damage carry their own lung-related risks. Cyclophosphamide, methotrexate, azathioprine, and mycophenolate have all been linked to pulmonary toxicity. With cyclophosphamide, the damage can come in two forms. An acute reaction may develop within the first several months and is sometimes reversible if caught early. A chronic form, however, can appear after months to years, producing lung fibrosis and pleural thickening that may continue to worsen even after the drug is stopped.24European Respiratory Review. Scleroderma lung disease The irony of treating a disease known for scarring lungs with a drug that can also scar lungs is not lost on clinicians. It is one of the reasons that decisions about immunosuppressive therapy in scleroderma require balancing the risk of doing too little against the toxicity of doing too much.
Early Palliative Care as a Parallel Track
Palliative care in scleroderma does not mean giving up on treatment. A newer model integrates palliative support alongside disease-directed therapy from early in the course. In a pilot program, half of the patients referred had their disease-directed management changed during palliative care consultations, and nearly all received psychological assessment and pharmacological support for symptoms like pain or nausea. The majority also accepted serious illness discussions and advance care planning conversations.25PubMed Central. Early, integrated systemic sclerosis palliative care for patients and their caregivers: description of a new model of care This is worth knowing because scleroderma is one of those diseases where quality of life can deteriorate significantly even while doctors are focused on keeping organs functional. Tight skin, chronic pain, difficulty eating, fatigue, and psychological distress all compound each other. Getting palliative input early does not shorten life. It tends to make the life you have considerably more livable, and in some chronic diseases it has even been associated with better survival outcomes.
Why Scleroderma Deaths May Be Undercounted
Death certificate studies of scleroderma face a persistent accuracy problem. Scleroderma is rare enough that the clinician filling out the certificate may record the immediate cause of death, such as heart failure, pulmonary hypertension, or kidney failure, without noting scleroderma as the underlying cause.26PubMed Central. Mortality from scleroderma in England and Wales 1968-1985. This means that population-level mortality statistics almost certainly underestimate the true toll of the disease. It also means that public health attention and research funding, which are partly driven by recorded death counts, may not reflect how dangerous scleroderma actually is. Advocacy groups have pushed for better coding and greater awareness among certifying physicians, but undercounting remains a real issue.